Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 10, 2022

SELL
$60.27 - $81.57 $4.6 Million - $6.23 Million
-76,335 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$65.85 - $96.21 $692,346 - $1.01 Million
10,514 Added 15.97%
76,335 $6.27 Million
Q3 2021

Nov 12, 2021

BUY
$73.2 - $107.87 $4.82 Million - $7.1 Million
65,821 New
65,821 $5.41 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.3B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Pathway Capital Management, LP Portfolio

Follow Pathway Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathway Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pathway Capital Management, LP with notifications on news.